• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

滤泡性淋巴瘤亚型中的微小RNA特征

MicroRNA signatures in subtypes of follicular lymphoma.

作者信息

Gebauer Niklas, Gollub Wiebke, Stassek Björn, Bernard Veronica, Rades Dirk, Feller Alfred C, Thorns Christoph

机构信息

Institut für Pathologie, Referenzzentrum für Lymphknotendiagnostik und Hämatopathologie, Universität zu Lübeck, 23538 Lübeck, Deutschland.

出版信息

Anticancer Res. 2014 May;34(5):2105-11.

PMID:24778012
Abstract

BACKGROUND

MicroRNAs are regulators of gene expression implicated in vital cellular processes including differentiation, cell growth and apoptosis. Distinct microRNA signatures have been identified for many malignancies including follicular lymphoma (FL). However, no microRNA expression profile characteristic of FL subtypes, e.g. FL with B-cell lymphoma-6 (BCL6) locus rearrangement (FL(BCL2+/BCL6+), FL(BCL2-/BCL6+)) or FL with diffuse growth pattern have been reported.

MATERIALS AND METHODS

MicroRNA signatures from 44 cases of FL were generated employing a quantitative real-time polymerase chain reaction approach. 15 cases of diffuse FL and 15 cases of FL(BCL2+/BCL6+)/FL(BCL2-/BCL6+) were compared against 14 cases of typical FL(BCL2+/BCL6-).

RESULTS

Numerous microRNAs were found to be differentially expressed between FL(BCL2+/BCL6+) and FL(BCL2-/BCL6+), as well as diffuse FL, when compared to typical cases of FL. Up-regulation of several oncogenic microRNAs as well as down-regulation of tumor-suppressor microRNAs was identified. Cluster analysis, however, revealed no microRNA signatures distinct from the reference group for either subtype.

CONCLUSION

These results indicate an involvement of microRNAs in the pathogenesis of FL and its subtypes. Marked de-regulation of oncogenic RNAs and tumor suppressors appears to correspond with a more aggressive phenotype frequently observed in FL(BCL2+/BCL6+), FL(BCL2-/BCL6+) and diffuse FL.

摘要

背景

微小RNA是基因表达的调节因子，参与包括分化、细胞生长和凋亡在内的重要细胞过程。已为包括滤泡性淋巴瘤（FL）在内的许多恶性肿瘤鉴定出独特的微小RNA特征。然而，尚未报道FL亚型（例如具有B细胞淋巴瘤-6（BCL6）基因座重排的FL（FL（BCL2+/BCL6+）、FL（BCL2-/BCL6+））或具有弥漫性生长模式的FL）的微小RNA表达谱。

材料和方法

采用定量实时聚合酶链反应方法生成44例FL的微小RNA特征。将15例弥漫性FL和15例FL（BCL2+/BCL6+）/FL（BCL2-/BCL6+）与14例典型的FL（BCL2+/BCL6-）进行比较。

结果

与典型的FL病例相比，发现FL（BCL2+/BCL6+）和FL（BCL2-/BCL6+）以及弥漫性FL之间有许多微小RNA差异表达。鉴定出几种致癌微小RNA的上调以及肿瘤抑制微小RNA的下调。然而，聚类分析显示，两种亚型均未发现与参考组不同的微小RNA特征。

结论

这些结果表明微小RNA参与了FL及其亚型的发病机制。致癌RNA和肿瘤抑制因子的明显失调似乎与FL（BCL2+/BCL6+）、FL（BCL2-/BCL6+）和弥漫性FL中经常观察到的更具侵袭性的表型相对应。

相似文献

1
MicroRNA signatures in subtypes of follicular lymphoma.滤泡性淋巴瘤亚型中的微小RNA特征
Anticancer Res. 2014 May;34(5):2105-11.
2
Bcl2-negative follicular lymphomas frequently have Bcl6 translocation and/or Bcl6 or p53 expression.Bcl2阴性的滤泡性淋巴瘤经常出现Bcl6易位和/或Bcl6或p53表达。
Pathol Int. 2007 Mar;57(3):148-52. doi: 10.1111/j.1440-1827.2006.02072.x.
3
Low-grade follicular lymphoma with t(14;18) presents a homogeneous disease entity otherwise the rest comprises minor groups of heterogeneous disease entities with Bcl2 amplification, Bcl6 translocation or other gene aberrances.伴有t(14;18)的低级别滤泡性淋巴瘤呈现为一种同质的疾病实体，否则其余部分则由伴有Bcl2扩增、Bcl6易位或其他基因异常的异质性疾病实体小群体组成。
Leukemia. 2005 Jun;19(6):1058-63. doi: 10.1038/sj.leu.2403738.
4
Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3.编码蛋白的B细胞分化基因在弥漫性大B细胞淋巴瘤和3级滤泡性淋巴瘤中的预后意义
Croat Med J. 2008 Oct;49(5):625-35. doi: 10.3325/cmj.2008.5.625.
5
BCL6-translocations affect the phenotype of follicular lymphomas only in the absence of t(14;18)IgH/BCL2.BCL6 易位仅在不存在 t(14;18)IgH/BCL2 的情况下影响滤泡性淋巴瘤的表型。
Anticancer Res. 2009 Nov;29(11):4649-55.
6
Utility of immunohistochemistry with an antibody against MYC at the initial diagnosis of follicular lymphoma, grade 3A, for predicting a more aggressive clinical course: a case report and review of the literature.抗MYC抗体免疫组化在滤泡性淋巴瘤3A级初诊时预测更具侵袭性临床病程的效用：一例病例报告及文献复习
Int J Clin Exp Pathol. 2015 Jun 1;8(6):7559-64. eCollection 2015.
7
Derivative (3)t(3;18)(q27;q21)t(18;16)(q21;?) involving the BCL2 and BCL6 genes in follicular lymphoma with t(3;14;18)(q27;q32;q21).在伴有t(3;14;18)(q27;q32;q21)的滤泡性淋巴瘤中，涉及BCL2和BCL6基因的衍生染色体(3)t(3;18)(q27;q21)t(18;16)(q21;?) 。
Cancer Genet Cytogenet. 2007 Nov;179(1):69-75. doi: 10.1016/j.cancergencyto.2007.08.012.
8
Frequencies of BCL2 and BCL6 translocations in representative Chinese follicular lymphoma patients: morphologic, immunohistochemical, and FISH analyses.中国典型滤泡性淋巴瘤患者中BCL2和BCL6易位的频率：形态学、免疫组织化学及荧光原位杂交分析
Diagn Mol Pathol. 2012 Dec;21(4):234-40. doi: 10.1097/PDM.0b013e3182585c3c.
9
Clinicopathological and prognostic significance of , , , and copy number gains and translocations in follicular lymphoma: a study by FISH analysis.滤泡性淋巴瘤中 、 、 、 和 拷贝数增益及易位的临床病理和预后意义：FISH 分析研究。
Leuk Lymphoma. 2020 Dec;61(14):3342-3350. doi: 10.1080/10428194.2020.1815017. Epub 2020 Sep 13.
10
Clinicopathological analysis of follicular lymphoma with BCL2, BCL6, and MYC rearrangements.伴有 BCL2、BCL6 和 MYC 重排的滤泡性淋巴瘤的临床病理分析。
Pathol Int. 2022 Jun;72(6):321-331. doi: 10.1111/pin.13223. Epub 2022 Mar 17.

引用本文的文献

1
Competitive Endogenous RNA Network Involving miRNA and lncRNA in Non-Hodgkin Lymphoma: Current Advances and Clinical Perspectives.非霍奇金淋巴瘤中涉及miRNA和lncRNA的竞争性内源性RNA网络：当前进展与临床展望
Biomedicines. 2021 Dec 17;9(12):1934. doi: 10.3390/biomedicines9121934.
2
The Multifaceted Role and Utility of MicroRNAs in Indolent B-Cell Non-Hodgkin Lymphomas.微小RNA在惰性B细胞非霍奇金淋巴瘤中的多方面作用及应用
Biomedicines. 2021 Mar 25;9(4):333. doi: 10.3390/biomedicines9040333.
3
Identification of Recurrent Mutations in the microRNA-Binding Sites of B-Cell Lymphoma-Associated Genes in Follicular Lymphoma.
鉴定滤泡性淋巴瘤中 B 细胞淋巴瘤相关基因的 microRNA 结合位点的反复突变。
Int J Mol Sci. 2020 Nov 20;21(22):8795. doi: 10.3390/ijms21228795.
4
The value of circulating microRNAs for early diagnosis of B-cell lymphoma: A case-control study on historical samples.循环 microRNAs 对 B 细胞淋巴瘤早期诊断的价值：一项基于历史样本的病例对照研究。
Sci Rep. 2020 Jun 15;10(1):9637. doi: 10.1038/s41598-020-66062-1.
5
Dysregulated MicroRNA Expression Profiles and Potential Cellular, Circulating and Polymorphic Biomarkers in Non-Hodgkin Lymphoma.非霍奇金淋巴瘤中失调的微小RNA表达谱及潜在的细胞、循环和多态性生物标志物
Genes (Basel). 2016 Dec 17;7(12):130. doi: 10.3390/genes7120130.